References
- Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med. 2009;6(8):2133–2142.
- Palma F, Volpe A, Villa P, et al. Writing group of AGATA study. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: the AGATA study. Maturitas. 2016;83:40–44.
- Stika CS. Atrophic vaginitis. Dermatol Ther. 2010;23(5):514–522.
- Krychman ML. Vaginal estrogens for the treatment of dyspareunia. J Sex Med. 2011;8(3):666–674.
- Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87–94.
- North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20:888–902.
- North American Menopause Society. The 2012 hormone therapy position statement of: the North American menopause society. Menopause. 2012;19:257–271.
- North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American menopause society. Menopause. 2007;14:357–369.
- Sturdee DW, Panay N. International menopause society writing group. recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13(6):509–522.
- Smith RN, Studd JW. Recent advances in hormone replacement therapy. Br J Hosp Med. 1993;49(11):799–808.
- Board of the International Menopause Society, Pines A, Sturdee DW, et al. IMS updated recommendations on postmenopausal hormone therapy. Climateric. 2007;10:181–194.
- SOGC Clinical Practice Guidelines. Menopause and osteoporosis update 2009. [accessed June 2019]. Available form: https://www.jogc.com/article/S1701-2163(16)34079-8/pdf
- Bachmann G. The estradiol vaginal ring–a study of existing clinical data. Maturitas. 1995;22:S21–S29.
- Cano A, Estevez J, Usandizaga R, et al. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. Menopause. 2012;19:1130–1139.
- Gerbaldo D, Ferraiolo A, Croce S, et al. Endometrial morphology after 12 months of vaginal oestriol therapy in postmenopausal women. Maturitas. 1991;13(4):269–274.
- Heimer G, Englund D. Effects of vaginally-administered oestriol on postmenopausal urogenital disorders: a cytohormonal study. Maturitas. 1992;14(3):171–179.
- Vooijts GP, Geurts T. Review of the endometrial safety during intravaginal treatment with estriol. Obstet Gynecol. 1995;62:101–106.
- Bachman GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician. 2000;61(10):3090–3096.
- Dessole S, Rubattu G, Ambrosini G, et al. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Menopause. 2004;11(1):49–56.
- Rueda C, Osorio AM, Avellaneda AC, et al. The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review. Climacteric. 2017;20(4):321–330.
- Chollet JA, Carter G, Meyn LA, et al. Efficacy and safety of vaginal estriol and progesterone in postmenopausal women with atrophic vaginitis. Menopause. 2009;16(5):978–983.